Information for the public
Afatinib is recommended as a possible treatment for adults with locally advanced or metastatic non-small-cell lung cancer if:
their cancer tests positive for the epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation and
they have not had a type of drug called an EGFR-TK inhibitor before.
If you have locally advanced or metastatic non-small-cell lung cancer as described above and your doctor thinks that afatinib is the right treatment, you should be able to have the treatment on the NHS.
Afatinib should be available on the NHS within 3 months of the guidance being issued.